文献速递血液透析通路

超声评估的病变形态与药物涂层球囊治疗血液透析患者自体动静脉内瘘新发功能障碍

Ultrasound-Assessed Lesion Morphology and Drug-Coated Balloon Treatment for de novo Dysfunctional Arteriovenous Fistula in Hemodialysis Patients.
PubMed 文献 · J Endovasc Ther · 2023-11-30

本研究为单中心回顾性研究,纳入114例新发功能障碍的自体动静脉内瘘病变患者,分别接受药物涂层球囊(DCB,n=48)或普通球囊(POBA,n=66)经皮腔内血管成形术。超声评估病变形态分为内膜增生型和收缩型,DCB组12个月一期通畅率显著高于POBA组(66.8±7.1% vs 35.9±6.3%,P=.006),其中收缩型病变DCB组通畅率也显著更高(61.9±10.6% vs 15.2±8.1%,P<.001),而内膜增生型两组无显著差异(P=.310)。

要点

  • DCB组12个月一期通畅率66.8±7.1%,显著高于POBA组的35.9±6.3%(P=.006)。
  • 收缩型病变中DCB组通畅率61.9±10.6%,显著高于POBA组的15.2±8.1%(P<.001)。
  • 内膜增生型病变中DCB组与POBA组通畅率无显著差异(P=.310)。

核心结论

  • 超声评估的病变形态对DCB与POBA的治疗效果有不同影响,DCB在收缩型病变中的疗效出乎意料地被证实。

研究设计与样本

  • 单中心回顾性研究,纳入114例新发功能障碍的自体动静脉内瘘病变患者(平均年龄73±10岁,男性69%),接受DCB(n=48)或POBA(n=66)经皮腔内血管成形术。

主要发现

  • DCB组12个月一期通畅率显著高于POBA组(66.8±7.1% vs 35.9±6.3%,P=.006)。
  • 内膜增生型病变中DCB组与POBA组12个月一期通畅率无显著差异(70.3±9.5% vs 45.9±8.0%,P=.310)。
  • 收缩型病变中DCB组12个月一期通畅率显著高于POBA组(61.9±10.6% vs 15.2±8.1%,P<.001)。
  • 交互分析显示病变形态对POBA与DCB组间再狭窄的风险比(HR)有显著差异(交互作用P=.031)。
  • 多因素分析显示DCB使用(aHR=0.49,95%CI:0.28-0.87,P=.015)、超声评估的收缩型病变(aHR=1.77,95%CI:1.07-2.93,P=.026)和狭窄位置(aHR=2.26,95%CI:1.15-4.46,P=.018)与PTA后AVF通畅率显著相关。

临床怎么用

  • 作者认为,基于DCB在收缩型病变中出乎意料的治疗效果的证实,可能不需要对收缩型病变犹豫使用DCB。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: This study aimed to evaluate the effect of ultrasound-assessed lesion morphology on the outcomes of drug-coated balloon (DCB) versus plain old balloon angioplasty (POBA) treatment for de novo dysfunctional arteriovenous fistulas (AVF) lesions. METHODS: This single-center retrospective study enrolled 114 consecutive patients (mean age, 73 ± 10 years; male, 69%) with de novo dysfunctional AVF lesions who underwent percutaneous transluminal angioplasty (PTA) using DCB (n = 48) and POBA (n = 66). The morphology of the stenotic lesions, evaluated using ultrasonography, was classified into intimal hyperplasia and shrinking types. The outcome measure was 12-month primary patency. Factors associated with loss of primary patency were evaluated using Cox proportional hazards models. RESULTS: The baseline characteristics were not significantly different between the 2 treatment groups. The 12-month primary patency rate was significantly higher in the DCB group than in the POBA group (66.8 ± 7.1% versus 35.9 ± 6.3%, P = .006). The 12-month primary patency rate in the lesions with intimal hyperplasia type was not significantly different (DCB: 70.3 ± 9.5% versus POBA: 45.9 ± 8.0%; P = .310), whereas that in the shrinking type was significantly higher in the DCB group than in the POBA group (61.9 ± 10.6% versus 15.2 ± 8.1%; P < .001). The interaction analysis demonstrated that lesion morphology had a significantly different hazard ratio (HR) for restenosis between the POBA and DCB groups (P for interaction = .031). The multivariate analysis revealed that DCB usage (adjusted hazard ratio [aHR], 0.49; 95% confidence interval [CI]: [0.28, 0.87]; P = .015), ultrasound-assessed lesion morphology (shrinking type: aHR, 1.77; 95% CI: [1.07, 2.93]; P = .026), and location of stenosis (aHR, 2.26; 95% CI: 1.15, 4.46; P = .018) were significantly associated with AVF patency after PTA. CONCLUSION: This study revealed that lesion morphology evaluated using ultrasonography had a differential impact on DCB and POBA outcomes. The therapeutic effect of DCB was unexpectedly confirmed in the shrinking type.Clinical ImpactThe effectiveness of DCB in inhibiting smooth muscle cell proliferation in intimal hyperplasia lesions was expected based on the known mechanism of action of paclitaxel. However the therapeutic effect of DCB was unexpectedly confirmed in the shrinking type too. We may not need to hesitate usage of DCB for shrinking type.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Suemitsu K, Shiraki T, Iida O, et al. Ultrasound-Assessed Lesion Morphology and Drug-Coated Balloon Treatment for de novo Dysfunctional Arteriovenous Fistula in Hemodialysis Patients. J Endovasc Ther. 2023. PMID: 38032055. doi:10.1177/15266028231215225

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。